viru
infect
possess
persist
health
challeng
swine
industri
lead
sever
econom
loss
worldwid
virus
oblig
intracellular
nanos
particl
depend
host
cell
machineri
propag
surviv
carri
deoxyribonucl
acid
dna
ribonucl
acid
rna
genom
materi
sever
virus
dna
rna
viru
famili
infect
produc
diseas
pig
mani
econom
import
swine
viral
infect
caus
consider
morbid
mortal
respons
signific
econom
loss
pork
industri
tabl
depend
cellular
tissu
tropism
virus
caus
patholog
chang
clinic
sign
associ
respiratori
system
reproduct
gastrointestin
tract
nervou
system
skin
extrem
alon
combin
porcin
reproduct
respiratori
syndrom
viru
prrsv
envelop
positivestrand
rna
viru
arterivirida
famili
caus
porcin
reproduct
respiratori
syndrom
prr
prr
respons
one
billion
dollar
loss
per
year
direct
indirect
cost
us
swine
industri
two
entir
distinct
genotyp
prrsv
circul
european
genotyp
north
american
countri
genotyp
caus
tremend
econom
loss
prrsv
transmit
oralnas
secret
semen
clinic
sign
includ
fever
anorexia
mild
sever
respiratori
problem
abort
reproduct
failur
common
pathogen
associ
porcin
respiratori
diseas
complex
prdc
swine
influenza
flu
constitut
anoth
persist
health
challeng
global
pig
industri
flu
infect
caus
influenza
viru
orthomyxovirida
famili
negativesens
singlestrand
segment
rna
genom
influenza
viru
transmit
direct
contact
infect
anim
contamin
fomit
aerosol
larg
droplet
clinic
sign
influenza
infect
includ
fever
anorexia
loss
weight
gain
respiratori
problem
influenza
associ
econom
loss
due
morbid
loss
bodi
weight
gain
increas
time
market
secondari
infect
medic
veterinari
expens
influenza
swine
origin
occasion
infect
human
even
lead
pandem
porcin
epidem
diarrhea
viru
pedv
transmiss
gastroenter
viru
tgev
porcin
deltacoronaviru
pdcov
enter
pathogen
young
pig
virus
belong
coronavirida
famili
positivesens
singlestrand
rna
genom
tgev
seriou
econom
damag
swine
industri
advent
vaccin
larg
control
pedv
still
result
high
morbid
mortal
neonat
piglet
clinic
sign
like
sever
diarrhea
vomit
dehydr
death
pedv
outbreak
us
led
billiondollar
loss
rotavirus
doublestrand
rna
virus
reovirida
famili
caus
enter
infect
pig
rotaviru
group
b
c
e
h
involv
porcin
enter
infect
porcin
rotavirus
also
zoonot
potenti
foot
mouth
diseas
fmd
anoth
highli
contagi
acut
viral
diseas
pig
etiolog
agent
fmd
viru
fmdv
positivesens
singlestrand
rna
viru
picornavirida
famili
fmdv
transmit
direct
contact
infect
anim
contamin
sourc
clinic
sign
includ
high
fever
appear
vesicular
lesion
extrem
saliv
lame
death
fmdv
caus
frequent
epizoot
mani
part
world
result
sever
econom
loss
food
insecur
trade
restrict
classic
swine
fever
csf
hog
cholera
result
high
morbid
mortal
pig
caus
csf
viru
csfv
envelop
positivesens
singlestrand
viru
flavivirida
famili
transmiss
csfv
occur
oralnas
rout
contact
infect
pig
contamin
resourc
even
vertic
infect
sow
piglet
clinic
sign
includ
fever
anorexia
respiratori
problem
neurolog
disord
reproduct
failur
death
csf
notifi
diseas
world
organ
anim
health
oie
econom
loss
associ
product
loss
trade
limit
tremend
expenditur
erad
program
exampl
outbreak
csfv
netherland
result
death
million
pig
econom
loss
billion
dollar
unit
state
free
csfv
howev
viru
endem
mani
part
world
includ
central
south
america
africa
asia
porcin
circoviru
singlestrand
dna
viru
circovirida
famili
caus
multisystem
diseas
refer
porcin
circovirusassoci
diseas
pcvad
transmit
horizont
well
vertic
direct
contact
effici
way
horizont
transmiss
viru
clinic
sign
infect
includ
poor
weight
gain
respiratori
problem
dermat
enter
nephropathi
reproduct
failur
five
genotyp
identifi
circul
high
preval
swine
herd
caus
signific
econom
loss
worldwid
porcin
parvoviru
ppv
common
caus
reproduct
failur
swine
herd
singlestrand
dna
viru
parvovirida
famili
transmit
oralnas
rout
stillbirth
mummif
embryon
death
infertil
smedi
syndrom
link
ppv
infect
convent
ppv
consid
genet
conserv
recent
evid
suggest
sever
virul
strain
emerg
due
high
mutat
rate
aujeszki
diseas
pseudorabi
pig
caus
suid
herpesviru
doubl
strand
dna
viru
belong
herpesvirida
famili
caus
agent
spread
primarili
direct
animaltoanim
nosetonos
sexual
contact
pseudorabi
character
nervou
disord
respiratori
problem
weight
loss
death
younger
piglet
reproduct
failur
one
devast
infecti
diseas
pig
industri
african
swine
fever
asf
caus
hemorrhag
infect
high
morbid
mortal
etiolog
agent
asf
viru
asfv
doubl
strand
dna
viru
asfarvirida
famili
viru
transmiss
occur
direct
contact
infect
anim
indirect
contact
fomit
soft
tick
speci
genu
ornithodoro
clinic
diseas
may
rang
asymptomat
infect
death
sign
acut
infect
character
high
fever
anorexia
erythema
respiratori
distress
reproduct
failur
pregnant
femal
death
asf
oie
notifi
diseas
unit
state
free
asfv
howev
viru
endem
domest
wild
pig
popul
mani
part
world
possibl
transmiss
us
nonendem
region
anim
trade
econom
loss
associ
product
loss
trade
limit
tremend
expenditur
erad
program
besid
rna
dna
virus
describ
mani
emerg
reemerg
virus
porcin
hepat
e
viru
porcin
endogen
retroviru
porcin
sapoviru
japanes
enceph
viru
encephalomyocard
viru
other
caus
variabl
degre
impact
swine
health
econom
loss
pig
industri
global
differ
type
vaccin
avail
econom
import
swine
virus
list
tabl
vaccin
prrsv
use
us
sinc
inactiv
modifiedl
viru
vaccin
avail
use
global
vaccin
effect
reduc
clinic
diseas
viremia
mainli
homolog
heterolog
infect
therefor
differ
strategi
ongo
develop
live
inactiv
subunit
mucos
prrsv
vaccin
induc
better
immun
broader
protect
swine
influenza
vaccin
also
effect
vaccin
strain
close
match
circul
strain
increas
immun
protect
vaccin
contain
multipl
strain
influenza
viru
iav
autogen
vaccin
wide
use
cocircul
multipl
lineag
iav
frequent
antigen
drift
respons
reduc
field
efficaci
current
swine
influenza
vaccin
moreov
commonli
use
whole
inactiv
iav
vaccin
administ
via
intramuscular
rout
induc
adequ
mucos
antibodi
cellular
immun
respons
suffer
matern
antibodi
interfer
young
piglet
even
caus
enhanc
respiratori
diseas
emerg
highli
virul
strain
pedv
recent
year
highlight
need
safe
effect
vaccin
porcin
enter
coronavirus
prevent
clinic
diseas
mortal
viru
shed
neonat
modifi
live
vaccin
rotaviru
avail
use
pig
rotaviru
efficaci
field
condit
question
indic
need
altern
porcin
rotaviru
manag
avail
inactiv
vaccin
provid
great
help
prevent
control
fmd
outbreak
mani
countri
howev
develop
vaccin
need
high
level
biocontain
facil
fmdv
serotyp
undergo
continu
antigen
drift
escap
vaccineinduc
immun
thu
fmd
vaccin
less
stringent
regulatori
procedur
multiserotyp
protect
efficaci
need
futur
safe
highli
efficaci
liveattenu
vaccin
avail
csfv
differenti
infect
vaccin
anim
diva
possibl
vaccin
limit
use
outbreak
control
diseas
erad
program
inactiv
whole
viru
subunit
vaccin
base
highli
adopt
pig
farm
efficaci
reduc
clinic
sign
improv
product
paramet
howev
infect
still
widespread
vaccin
farm
replac
recent
part
contribut
select
pressur
exhibit
vaccin
highlight
need
vaccin
protect
multipl
genotyp
current
use
inactiv
vaccin
porcin
parvo
viru
protect
old
ppv
strain
newli
emerg
strain
demand
efficaci
vaccin
fortun
pseudorabi
erad
mani
countri
includ
us
use
inactiv
attenu
vaccin
togeth
stringent
biosecur
measur
howev
still
problemat
diseas
mani
countri
includ
china
also
maintain
feral
swine
popul
countri
frequent
emerg
virul
strain
even
vaccin
herd
demand
updat
vaccin
technolog
achiev
effici
control
ultim
global
erad
pseudorabi
vaccin
avail
far
asfv
control
measur
depend
entir
earli
identif
cull
infect
herd
adopt
strict
sanitari
measur
vaccin
develop
hinder
antigen
divers
multitud
immuneevas
strategi
use
viru
effect
vaccin
definit
help
control
erad
asfv
endem
countri
prevent
geograph
expans
porcin
epidem
diarrhea
ped
rna
particl
inactiv
liveattenu
viru
asia
protect
immun
respons
sow
better
mucos
immun
foot
mouth
diseas
fmd
inactiv
viru
less
stringent
requir
vaccin
product
protect
multipl
serotyp
classic
swine
fever
csf
liveattenu
viru
diva
potenti
porcin
circoviru
associ
diseas
pcvad
inactiv
recombin
subunit
multigenotyp
protect
porcin
parvoviru
infect
inactiv
viru
protect
novel
strain
pseudorabi
inactiv
liveattenu
viru
protect
novel
emerg
strain
african
swine
fever
asf
none
novel
crossprotect
vaccin
import
nanoparticlebas
vaccin
deliveri
platform
develop
vaccin
made
signific
impact
reduc
viral
infecti
diseas
burden
human
anim
howev
still
mani
diseas
either
vaccin
need
substanti
improv
exist
one
past
decad
nanoparticl
np
base
technolog
elicit
signific
interest
develop
novel
vaccin
candid
offer
multipl
benefit
inactiv
viru
subunit
solubl
antigen
npsbase
vaccin
nanovaccin
prepar
either
encapsul
vaccin
compon
within
np
decor
particl
surfac
viral
antigen
np
protect
antigen
proteolyt
degrad
prolong
bioavail
maintain
slow
sustain
antigen
releas
properti
help
induct
better
immun
respons
compar
solubl
antigen
vaccin
differ
mechan
use
variou
np
facilit
immun
modul
antigen
present
cell
apc
depict
graphic
figur
briefli
np
enhanc
antigen
adsorpt
uptak
apc
also
facilit
antigen
process
mechan
np
induc
matur
dc
promot
antigen
crosspresent
major
histocompat
complex
mhc
class
cell
induc
product
differ
innat
cytokin
regul
humor
cellular
immun
respons
npsload
antigen
readili
phagocytos
apc
solubl
antigen
moreov
dendrit
cell
dc
key
player
involv
bridg
innat
adapt
immun
preferenti
intern
np
compar
microparticl
nm
exampl
poli
lacticcoglycol
acid
plga
particl
size
nm
encapsul
ovalbumin
test
mous
bonemarrow
deriv
dendrit
cell
nm
size
particl
taken
effici
compar
larger
one
nm
size
plga
np
result
greater
activ
dc
stronger
antigenspecif
cell
respons
immun
mice
compar
solubl
antigen
larger
particl
besid
control
deliveri
antigen
np
also
provid
adjuvantlik
function
vaccin
adjuv
either
work
antigen
deliveri
system
facilit
antigen
uptak
present
apc
activ
innat
immun
receptor
cytokin
product
maturationmigr
dc
adjuvantinduc
innat
immun
respons
determin
type
adapt
immun
respons
gener
helper
versu
helper
bias
immun
alum
wide
use
adjuv
human
safe
inexpens
compat
prove
favor
differ
vaccin
antigen
howev
despit
induc
potent
antibodi
respons
alum
weakinduc
cellmedi
immun
advers
reaction
observ
inject
site
alumbas
adjuv
veterinari
vaccin
oilinwat
emuls
saponin
common
adjuv
also
caus
advers
reaction
inject
site
number
adjuv
avail
parenter
vaccin
limit
option
avail
intranas
altern
rout
immun
np
serv
altern
adjuv
human
anim
use
act
antigen
deliveri
system
activ
innat
immun
respons
modern
vaccin
approach
shift
tradit
whole
pathogenbas
antigen
small
fraction
subunit
pathogen
howev
purifi
whole
inactiv
pathogen
subunit
recombin
antigen
poorli
immunogen
requir
potent
immunostimulatori
platform
augment
immun
respons
achiev
npsbase
technolog
npsbase
platform
use
deliv
multipl
antigen
antigenadjuv
combin
improv
antigen
uptak
concurr
activ
apc
lead
innat
immun
program
codeliveri
cpg
oligodeoxynucleotid
tetanu
toxoid
nanospher
induc
significantli
greater
cell
prolif
respons
time
greater
igg
antibodi
isotyp
mice
subcutan
immun
compar
group
receiv
tetanu
toxoid
cpg
oligodeoxynucleotid
solubl
form
likewis
codeliveri
melanoma
antigen
tolllik
receptor
tlr
agonist
plga
np
induc
therapeut
antitumor
effect
mediat
potent
cell
activ
np
surfac
modifi
target
microfold
cell
macrophag
dc
could
use
mucos
vaccin
oral
nasal
mucos
rout
immun
mice
surfac
coat
plga
np
encapsul
hepat
b
viru
vaccin
antigen
lectin
result
effici
target
oral
deliv
np
mucos
cell
induc
secretari
iga
antibodi
respons
mucos
surfac
likewis
dc
target
chitosan
np
load
plasmid
dna
encod
nucleocapsid
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
induc
better
nucleocapsid
proteinspecif
mucos
iga
antibodi
respons
compar
solubl
unentrap
antigen
nasal
immun
mice
target
tcell
mediat
immun
respons
critic
protect
intracellular
pathogen
virus
benefici
npsdeliv
antigen
use
antigen
crosspresent
cytotox
lymphocyt
ctl
develop
robust
cellmedi
immun
respons
plgabas
particul
vaccin
shown
induc
effici
tcell
immun
mice
pig
similarli
rodent
pig
studi
shown
polyanhydrid
npsbase
vaccin
also
enhanc
cellular
immun
thu
immunogen
properti
differ
polymerbas
np
could
exploit
improv
efficaci
vaccin
use
porcin
viral
infect
review
studi
conduct
pig
relat
develop
evalu
npsbase
vaccin
candid
use
viruslik
particl
vlp
biodegrad
polym
polysaccharid
liposom
porcin
viral
infect
includ
tabl
vlp
construct
use
viral
structur
protein
selfassembl
noninfecti
lack
viral
genom
materi
vlp
mimic
virion
effect
induc
innat
adapt
immun
respons
vlp
produc
use
differ
bacteri
insect
yeast
mammalian
express
system
due
smaller
size
particul
natur
vlpsbase
vaccin
process
present
mhc
class
ii
also
mhc
class
pathway
lead
gener
antibodi
well
ctl
respons
potenti
use
vlp
porcin
viral
vaccin
develop
evid
success
commerci
human
papilloma
viru
hpv
hepat
b
viru
malaria
vaccin
adapt
technolog
one
studi
prrsv
vlp
contain
five
two
viral
surfac
protein
gener
use
baculoviru
express
system
prrsv
vlp
vaccin
mix
ratio
mycobacterium
tuberculosi
whole
cell
lysat
tuberculosi
wcl
adjuv
administ
pig
vlpsvaccin
pig
partial
protect
reduct
viru
titer
lung
vlpsvaccin
pig
also
enhanc
respons
compar
mock
challeng
pig
howev
anoth
studi
pig
vaccin
prrsv
vlp
express
n
e
protein
enhanc
viremia
accompani
higher
level
cytokin
respons
observ
contrast
result
prrsv
vlp
studi
suggest
need
research
fulli
evalu
potenti
vlpsbase
prrsv
vaccin
swine
influenzaassoci
vlp
express
ha
na
protein
pandem
viru
inocul
twice
intramuscularli
without
emulsigen
mvp
lab
usa
adjuv
pig
vaccin
induc
robust
serum
igg
mucos
iga
viru
neutral
antibodi
respons
pig
homolog
viru
challeng
vlpsvaccin
pig
significantli
reduc
pneumon
lesion
viru
titer
substanti
lower
upper
lower
respiratori
tract
compar
mock
vaccin
anim
mani
studi
conduct
goal
develop
vlpsbase
fmdv
vaccin
use
variou
express
system
encod
differ
viral
antigen
rabbit
hemorrhag
diseas
viru
rhdv
vlp
express
tcell
epitop
protein
fmdv
gener
vlp
vaccin
induc
matur
bone
marrow
deriv
dendrit
cell
vitro
pig
immun
im
togeth
montanid
isa
adjuv
seppic
franc
induc
higher
serum
igg
iga
antibodi
respons
vaccin
also
increas
number
secret
cell
lymphoprolif
respons
pbmc
compar
vaccin
deliv
without
adjuv
inocul
pig
howev
challeng
experi
perform
guo
et
al
construct
fmdv
vlp
express
capsid
protein
immun
pig
im
rout
vlpsvaccin
pig
produc
virusspecif
neutral
antibodi
respons
peripher
blood
mononuclear
cell
pbmc
good
inactiv
fmdv
vaccin
control
challeng
homolog
viru
vlpsvaccin
pig
show
specif
clinic
sign
anoth
studi
epitop
peptid
fmdv
insert
coat
protein
gene
malespecif
coliphag
vlp
inject
im
pig
formul
result
induct
viru
neutral
antibodi
protect
immun
pig
compar
protect
peptid
alon
vaccin
anim
howev
protect
lower
inactiv
vaccin
indic
need
improv
vlp
either
use
longer
sequenc
epitop
addit
adjuv
vlp
gener
insert
epitop
fmdv
porcin
parvoviru
administ
im
pig
vlpsvaccin
induc
higher
viru
neutral
antibodi
compar
synthet
peptid
vaccin
result
better
protect
challeng
fmdv
infect
vlp
also
develop
test
porcin
neurotrop
virus
porcin
encephalomyocard
viru
emcv
vlp
contain
structur
protein
nonstructur
protein
proteas
gener
im
administr
togeth
montanid
im
n
vg
adjuv
seppic
vlpsvaccin
induc
sustain
product
viru
neutral
antibodi
compar
commerci
vaccin
control
absenc
sever
inject
site
reaction
vlpsvaccin
pig
suggest
potenti
develop
vlpsbase
vaccin
emcv
diseas
pig
likewis
recent
studi
japanes
enceph
viru
genotyp
gi
vlp
encod
premembran
prm
envelop
e
protein
construct
subcutan
immun
vaccin
formul
induc
robust
neutral
antibodi
respons
protect
homolog
gi
heterolog
giii
jev
virus
find
indic
crossprotect
potenti
vlpsbase
jev
vaccin
pig
earli
studi
vlp
use
full
length
cap
protein
escherichia
coli
express
system
pig
vaccin
use
cap
vlp
isa
adjuv
seppic
im
rout
induc
capspecif
igg
antibodi
vaccin
anim
appar
healthi
normal
bodi
weight
gain
absenc
clinic
sign
diseas
li
et
al
show
induct
capspecif
igg
antibodi
pig
vaccin
subcutan
sc
inject
cap
vlp
vaccin
pig
demonstr
reduc
fever
viremia
mild
patholog
chang
lung
lymph
node
compar
unvaccin
challeng
anim
anoth
studi
vlp
coexpress
cap
protein
porcin
gmcsf
administ
im
pig
vaccin
formul
induc
significantli
higher
viru
neutral
antibodi
pig
viru
challeng
vlpsvaccin
pig
normal
bodi
weight
gain
compar
cap
protein
alon
commerci
vaccin
group
viru
clearanc
howev
observ
equal
vlp
well
control
vaccin
group
singl
vlpsbase
vaccin
studi
porcin
parvoviru
found
ppvvlp
express
major
structur
protein
administ
im
doubl
oil
emuls
doe
miner
oil
adjuv
wean
pig
induct
significantli
higher
neutral
antibodi
vlpsvaccin
anim
compar
inactiv
vaccin
group
gilt
immun
formul
challeng
virul
ppv
viru
detect
fetus
thu
ppvvlp
potenti
vaccin
candid
prevent
ppvinduc
reproduct
failur
summari
vlp
variou
origin
use
develop
effici
vaccin
porcin
viral
infect
studi
need
evalu
immunogen
protect
efficaci
field
condit
plga
copolym
lactic
acid
glycol
acid
wide
explor
synthet
polym
vaccin
studi
safe
nontox
compound
hydrolysi
product
readili
assimil
exist
metabol
pathway
plga
nanoparticl
prepar
either
oil
water
emulsif
nanoprecipit
method
plga
np
bear
net
neg
charg
enter
apc
pinocytosi
endocytosi
undergo
revers
charg
endolysosom
escap
entrap
vaccin
cargo
lead
antigen
process
cytoplasm
result
crosspresent
antigen
cell
mhc
class
pathway
plga
np
involv
matur
dc
mice
human
origin
control
releas
entrap
antigen
lead
effici
expans
differenti
memori
tcell
rodent
studi
induct
robust
tcell
immun
observ
plga
npsbase
vaccin
contain
variou
vaccin
antigen
plga
approv
drug
deliveri
human
us
food
drug
administr
fda
european
medicin
agenc
ema
plga
np
enhanc
antigen
uptak
induc
matur
porcin
apc
singl
dose
immun
plga
npsencapsul
inactiv
kill
prrsv
antigen
npskag
induc
activ
innat
natur
killer
nk
cell
tcell
secret
innat
cytokin
npskag
vaccin
also
induc
greater
frequenc
cell
increas
secret
lower
frequenc
tregulatori
cell
reduc
secret
inflammatori
cytokin
compar
control
kagvaccin
anim
subsequ
studi
npskag
coadminist
tuberculosi
wcl
adjuv
balanc
immun
respons
augment
mucos
iga
antibodi
respons
observ
heterolog
prrsv
challeng
pig
receiv
npsbase
vaccin
show
clinic
sign
also
signific
reduct
lung
viru
load
plga
np
also
use
encapsul
highli
conserv
influenza
peptid
evalu
efficaci
pig
administr
plga
npsbase
subunit
vaccin
result
induct
epitopespecif
tcell
respons
antibodi
respons
tcell
bias
immun
respons
also
observ
pig
immun
plga
npsencapsul
inactivatedkil
influenza
viru
plgakag
vaccin
pig
plgakag
vaccin
administ
anim
observ
reduc
fever
lower
pneumon
lesion
increas
viru
clearanc
lung
heterolog
viru
challeng
compar
kag
vaccin
control
anoth
studi
pedv
kag
encapsul
plga
np
use
immun
pregnant
sow
rout
nanovaccin
induc
higher
virusspecif
igg
neutral
antibodi
serum
greater
igg
iga
neutral
antibodi
respons
colostrum
also
induc
greater
cell
prolifer
respons
restimul
pbmc
compar
kag
vaccin
control
importantli
piglet
born
npsvaccin
sow
higher
viru
neutral
antibodi
better
protect
homolog
viru
challeng
kag
control
studi
suggest
plga
np
use
effici
mean
enhanc
virusspecif
cellmedi
immun
respons
pig
polyanhydrid
anoth
type
synthet
polym
wide
studi
vaccin
deliveri
polyanhydrid
np
synthes
polycondens
emulsif
process
biodegrad
biocompat
safe
vaccin
deliveri
activ
innat
immun
respons
manner
similar
lipopolysaccharid
lp
surfaceerod
natur
polyanhydrid
np
provid
safe
microenviron
encapsul
antigen
facilit
slow
sustain
antigen
releas
induct
better
antibodi
cellmedi
immun
respons
polyanhydrid
npsbase
vaccin
report
viral
bacteri
parasit
infect
inocul
polyanhydrid
npsbase
siv
kag
vaccin
kagnanovaccin
rout
enhanc
cellmedi
antibodi
respons
pig
heterolog
viru
challeng
kagnanovaccin
group
six
eightfold
reduct
nasal
viru
shed
compar
kag
vaccin
control
subsequ
studi
kagnanovaccin
formul
supplement
cpgodn
adjuv
cellmedi
well
mucos
iga
antibodi
respons
improv
heterolog
viru
challeng
cpgodnadjuv
kagnanovaccin
provid
better
protect
signific
reduct
influenzainduc
fever
reduct
nasal
viru
shed
reduct
lung
viru
titer
compar
pig
immun
fivetim
greater
quantiti
solubl
kill
antigen
kag
vaccin
studi
also
indic
dosespar
abil
polyanhydrid
np
thu
polyanhydrid
np
also
use
induc
better
cellular
well
humor
immun
respons
pig
chitosan
algin
polysaccharid
also
attract
attent
materi
np
formul
drug
deliveri
studi
chitosan
natur
polym
deriv
deacetyl
chitin
compos
glucosamin
nacetylglucosamin
residu
due
avail
amino
carboxyl
group
acid
microenviron
chitosan
np
net
posit
surfac
charg
make
highli
mucoadhes
increas
halftim
antigen
retent
mucos
surfac
chitosan
np
revers
open
epitheli
cell
tight
junction
therebi
improv
paracellular
intracellular
antigen
transport
across
mucos
epitheli
surfac
chitosan
np
also
enhanc
antigen
uptak
apc
induc
apc
matur
activ
secret
innat
cytokin
thu
chitosan
np
form
attract
mucos
vaccin
deliveri
vehicl
chitosanbas
np
use
pig
deliv
adjuv
bee
venom
plasmid
encod
porcin
gene
improv
induct
better
virusspecif
immun
respons
respect
vaccin
prrsv
chitosan
np
enhanc
antigen
uptak
porcin
apc
activ
produc
innat
cytokin
includ
ifnalpha
tnfalpha
chitosan
np
encapsul
siv
kag
cnpskag
vaccin
administ
twice
rout
without
addit
adjuv
pig
induc
crossreact
mucos
iga
antibodi
chitosan
npsbase
vaccin
also
induc
respons
pbmc
tracheobronchi
lymph
node
tbln
better
kag
vaccin
control
vaccin
formul
substanti
reduc
challeng
heterolog
viru
titer
upper
lower
respiratori
tract
compar
solubl
kag
vaccin
find
emphas
potenti
benefit
use
chitosan
np
futur
develop
mucos
swine
influenza
vaccin
pig
recent
dendrimerlikealphadglucan
np
deriv
sweet
corn
varieti
examin
altern
safe
costeffect
potent
adjuv
posit
charg
np
effici
adsorb
neg
charg
antigen
electrostat
interact
rodent
studi
shown
np
enhanc
antigen
uptak
dc
induc
matur
activ
produc
proinflammatori
cytokin
help
induct
antigenspecif
antibodi
recent
studi
observ
np
without
addit
siv
kill
antigen
kag
stimul
porcin
apc
produc
cytokin
pig
immun
via
rout
np
adsorb
siv
kag
twotoon
ratio
kag
result
crossreact
mucos
iga
respons
better
kag
control
moreov
pig
immun
im
adsorb
ovalbumin
ova
significantli
greater
antibodi
serum
compar
pig
vaccin
ova
alon
find
highlight
possibl
use
cornderiv
np
potenti
adjuv
porcin
viral
vaccin
develop
liposom
encapsul
hydrophil
hydrophob
molecul
aqueou
nonaqu
phase
vesicl
liposom
vesicl
protect
antigen
enzymat
degrad
enhanc
antigen
intern
apc
maintain
control
releas
antigen
liposomeencapsul
antigen
enhanc
cellular
humor
immun
respons
pig
studi
liposom
np
use
im
adjuv
dna
vaccin
liposom
npsadjuv
induc
higher
neutral
antibodi
respons
pig
reduc
viremia
challeng
viru
compar
alumadjuv
vaccin
provid
evid
liposom
np
potent
adjuv
pig
recent
studi
use
liposom
np
encapsul
ten
highli
conserv
peptid
differ
influenza
virus
human
pig
origin
immun
pig
rout
coadminist
monosodium
urat
msu
crystal
adjuv
liposomeadjuv
base
vaccin
enhanc
mucos
iga
antibodi
respons
induc
peptid
virusspecif
thelpermemori
cell
respons
result
reduc
fever
modest
reduct
viru
titer
respiratori
tract
pig
studi
highlight
fact
liposomebas
np
use
attract
vaccin
deliveri
platform
porcin
viral
infect
viru
infect
signific
impact
pig
industri
worldwid
use
avail
vaccin
definit
help
achiev
strong
control
porcin
viral
infect
food
mouth
diseas
transmiss
gastroenter
classic
swine
fever
pseudorabi
vaccin
also
help
reduc
clinic
sign
increas
product
paramet
diseas
howev
mani
porcin
virus
improv
exist
vaccin
platform
develop
novel
vaccin
deliveri
system
necessari
induc
better
mucos
cellmedi
immun
protect
emerg
reemerg
strain
enhanc
breadth
heterolog
crossgenotyp
heterosubtyp
immun
differenti
infect
vaccin
anim
npsbase
vaccin
deliveri
platform
vlp
biodegrad
polym
liposom
great
potenti
protect
vaccin
antigen
degrad
facilit
antigen
uptak
process
apc
impart
adjuv
potenti
use
mucos
altern
rout
immun
induc
effect
mucos
cellular
crossprotect
broader
immun
research
effort
ongo
develop
porcin
viral
vaccin
use
npsbase
technolog
howev
collabor
indepth
studi
warrant
make
innov
vaccin
antigen
deliveri
technolog
success
practic
applic
food
anim
industri
date
almost
immunomodulatori
mechan
npsbase
vaccin
deliveri
platform
studi
rodent
diseas
model
may
may
reflect
situat
pig
domest
anim
speci
likewis
proper
understand
effect
size
charg
physicochem
properti
np
deliveri
differ
rout
immun
pig
necessari
make
effici
translat
robust
npsbase
vaccin
technolog
similarli
studi
also
focu
np
stabil
differ
storag
condit
immunogen
long
period
time
directli
associ
commerci
aspect
vaccin
product
recent
advanc
npsbase
adjuv
vaccin
deliveri
platform
pig
demonstr
great
promis
yield
better
candid
vaccin
mani
porcin
viral
infect
enhanc
efficaci
field
nanovaccin
technolog
also
adopt
develop
effect
vaccin
viral
infect
anim
speci
knowledg
gain
could
exploit
improv
efficaci
exist
human
viral
vaccin
